Mostrar el registro sencillo del ítem

dc.contributor.authorHerrera M.I.
dc.contributor.authorKölliker-Frers R.A.
dc.contributor.authorOtero-Losada M.
dc.contributor.authorPerez Lloret S.
dc.contributor.authorFilippo M.
dc.contributor.authorTau J.
dc.contributor.authorCapani F.
dc.contributor.authorVilla A.M.
dc.date.accessioned2020-09-02T22:20:27Z
dc.date.available2020-09-02T22:20:27Z
dc.date.issued2019
dc.identifier10.3389/fneur.2019.01046
dc.identifier.citation10, , -
dc.identifier.issn16642295
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4874
dc.descriptionObjective: To test the feasibility of conducting a full-scale project evaluating the potential value of the phosphorylated neurofilament H (pNF-H) and several cytokines as disability markers in relapsing-remitting multiple sclerosis (RRMS). Methods: Twenty-four patients with 5-year RRMS evolution and eleven healthy control subjects entered the study. None of the participants had an inflammatory systemic or metabolic disease. Disability progression was evaluated using the Expanded Disability Status Scale. Serum level of pNF-H, the anti-inflammatory cytokine transforming growth factor-β 1 (TGF-β1), and the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17A (IL-17A), monocyte chemotactic protein-1 (MCP-1), and soluble intercellular cell-adhesion molecule 1 (sICAM-1) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: The patients had higher serum level of TGF-β1, IL-6, sICAM-1, and pNF-H. Based on these findings, a sample of at least 49 controls and 89 recent-onset RRMS patients is required to find an at least 1-point between-group difference in pNF-H with a power of 80% and an α error = 0.05. The progression of the disease was correlated with the level of pNF-H (Spearman rho = 0.624, p = 0.006), but not with the cytokines'. Conclusions: The serum level of pNF-H, EDSS score-correlated, might stand for a potential biomarker of disability in RRMS reflecting progressive axonal damage and cumulative neurological deterioration. The novelty of these results warrants conducting a larger confirmatory trial. © Copyright © 2019 Herrera, Kölliker-Frers, Otero-Losada, Perez Lloret, Filippo, Tau, Capani and Villa.
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.subjectbiomarker potential
dc.subjectcytokines
dc.subjectdisability progression
dc.subjectexpanded disability status scale
dc.subjectneurofilament heavy chain phosphoform
dc.subjectrelapsing-remitting multiple sclerosis
dc.subjectcytokine
dc.subjectintercellular adhesion molecule 1
dc.subjectinterleukin 17
dc.subjectinterleukin 1beta
dc.subjectinterleukin 6
dc.subjectinterleukin 8
dc.subjectmonocyte chemotactic protein 1
dc.subjectneurofilament H protein
dc.subjectneurofilament protein
dc.subjecttransforming growth factor beta1
dc.subjecttumor necrosis factor
dc.subjectunclassified drug
dc.subjectadult
dc.subjectArticle
dc.subjectaxonal injury
dc.subjectcase study
dc.subjectclinical article
dc.subjectclinical evaluation
dc.subjectcontrolled study
dc.subjectcorrelational study
dc.subjectcross-sectional study
dc.subjectdeterioration
dc.subjectdisease exacerbation
dc.subjectdisease marker
dc.subjectenzyme linked immunosorbent assay
dc.subjectExpanded Disability Status Scale
dc.subjectfeasibility study
dc.subjectfemale
dc.subjecthuman
dc.subjectimmunomodulation
dc.subjectmale
dc.subjectmetabolic disorder
dc.subjectmultiple sclerosis
dc.subjectobservational study
dc.subjectpilot study
dc.subjectprotein blood level
dc.subjectprotein phosphorylation
dc.subjectscoring system
dc.titleA Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis
dc.typeArticle


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem